Establishing Research With Horizon Therapeutics' Robert Stoffel, Ph.D.
![23_01_BPO_BusBiotech_1200x628_Ep160 23_01_BPO_BusBiotech_1200x628_Ep160](https://vertassets.blob.core.windows.net/image/c600b768/c600b768-db70-43f1-b167-cf66ea5edcd6/375_250-23_01_bpo_busbiotech_1200x628_ep160.jpg)
Horizon Therapeutics has made plenty of waves in the biotech news cycle of late. While perhaps not as flashy as a perilous multibillion-dollar acquisition deal or potential blockbuster readout, its formal establishment of a research team – comparatively pragmatic as that may be – could have long-term consequences that are just as impactful. On this week's episode of the Business of Biotech, we dig into why the company chose to establish a research function, learn why it chose Dr. Robert Stoffel, Ph.D. to run it, and get a step-by-step explainer on how Stoffel went about establishing the department, setting its goals and strategy, staffing it, and integrating it across teams at the fast-rising biopharmaceutical company.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.